top of page
Recent Research
Little hope in TIGIT trials to date
As expected, TIGIT addition to PD1 failed to beat chemo in second-line patients.
The failure of Merck’s TIGIT+PD1 combo to beat second line
Mar 20, 2023
Roche: Maintaining Leadership is difficult: nearterm pipeline outlook
We undertake a detailed analysis of seven near term Roche pipeline assets, spanning Roche’s market leading positions in Non-Hodgkin...
Aug 14, 2022
ROG: No rays of hope for TIGIT at ASCO2022
Roche recently announced the failure of co-primary progression free survival endpoints in both of its 1st line TIGIT trials in non-small (SK
Jun 22, 2022
Archive
Search By Tags
Follow Us
Bloomberg: FOVL <go>
ThomsonReuters
FactSet
Captial IQ
bottom of page